Maino Alessandro, Di Stasio Enrico, Grimaldi Maria Chiara, Cappannoli Luigi, Rocco Erica, Vergallo Rocco, Biscetti Federico, Baroni Silvia, Urbani Andrea, Landolfi Raffaele, Biasucci Luigi Marzio
Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie, Università Cattolica del Sacro Cuore, Roma, Italy; Dipartimento di scienze laboratoristiche ed infettivologiche, UOC Chimica, Biochimica e Biologia Molecolare Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
Int J Cardiol. 2021 Sep 1;338:278-285. doi: 10.1016/j.ijcard.2021.06.028. Epub 2021 Jun 19.
Coronavirus disease 2019 (COVID-19) is a pandemic disease that is causing a public health emergency. Characteristics and clinical significance of myocardial injury remain unclear.
This retrospective single-center study analyzed 189 patients who received a COVID-19 diagnosis out of all 758 subjects with a high sensitive troponin I (Hs-TnI) measurement within the first 24 h of admission at the Policlinico A.Gemelli (Rome, Italy) between February 20th 2020 to April 09th 2020.
The prevalence of myocardial injury in our COVID-19 population is of 16%. The patients with cardiac injury were older, had a greater number of cardiovascular comorbidities and higher values of acute phase and inflammatory markers and leucocytes. They required more frequently hospitalization in Intensive Care Unit (10 [32.3%] vs 18 [11.4%]; p = .003) and the mortality rate was significantly higher (17 [54.8%] vs. 15 [9.5%], p < .001). Among patients in ICU, the subjects with myocardial injury showed an increase need of endotracheal intubation (8 out of 9 [88%] vs 7 out of 19[37%], p = .042). Multivariate analyses showed that hs-TnI can significantly predict the degree of COVID-19 disease, the intubation need and in-hospital mortality.
In this study we demonstrate that hs-Tn can significantly predict disease severity, intubation need and in-hospital death. Therefore, it may be reasonable to use Hs-Tn as a clinical tool in COVID-19 patients in order to triage them into different risk groups and can play a pivotal role in the detection of subjects at high risk of cardiac impairment during both the early and recovery stage.
2019年冠状病毒病(COVID-19)是一种正在引发公共卫生紧急事件的大流行病。心肌损伤的特征和临床意义仍不清楚。
这项回顾性单中心研究分析了2020年2月20日至2020年4月9日期间在意大利罗马的A. Gemelli综合医院入院后24小时内进行高敏肌钙蛋白I(Hs-TnI)检测的758名受试者中的189例COVID-19确诊患者。
我们的COVID-19患者群体中心肌损伤的患病率为16%。心脏损伤患者年龄更大,心血管合并症更多,急性期和炎症标志物及白细胞值更高。他们更频繁地需要入住重症监护病房(10例[32.3%]对18例[11.4%];p = 0.003),死亡率显著更高(17例[54.8%]对15例[9.5%],p < 0.001)。在重症监护病房的患者中,心肌损伤患者显示出更高的气管插管需求(9例中的8例[88%]对19例中的7例[37%],p = 0.042)。多变量分析表明,Hs-TnI可以显著预测COVID-19疾病的严重程度、插管需求和住院死亡率。
在本研究中,我们证明Hs-Tn可以显著预测疾病严重程度、插管需求和住院死亡。因此,将Hs-Tn用作COVID-19患者的临床工具,以便将他们分类到不同风险组中,并在早期和恢复阶段检测心脏损伤高风险受试者时发挥关键作用可能是合理的。